MET, a receptor tyrosine kinase, is crucial in cell processes and is implicated in NSCLC, with MET exon 14 skipping mutations in 3%–5% of cases and amplifications in 1%–5% of NSCLC patients, effectively treated with drugs like crizotinib, capmatinib, savolitinib, and tepotinib. Here, NTRK1 is linked to non-small cell lung carcinoma.